Sermorelin dosage for muscle growth is a search that assumes a settled protocol already exists. It does not. Sermorelin is a growth-hormone-releasing hormone (GHRH) analog, and almost every controlled study of it was run in older adults with age-related decline in growth hormone, not in healthy lifters chasing hypertrophy. The doses used in that research are on record. What they actually show about building muscle is a narrower, more mixed story than most product pages let on.
The Compound Universe Take: Published research used sermorelin-class doses ranging from a fixed 2 mg nightly injection (no measurable change in muscle) up to about 10 mcg per kg of body weight nightly, which produced a modest 1.26 kg lean-mass gain in men over 16 weeks but nothing in women. The one FDA-reviewed dose, 30 mcg per kg daily, was approved for pediatric growth failure, not muscle building. No trial has tested a sermorelin dosage specifically for muscle growth in healthy training adults, and no sermorelin product is currently FDA-approved for any indication. Treat every figure below as study data, not a dosing guide.
New here? See peptides researched for muscle growth to place sermorelin among the compounds studied for this goal.
What “sermorelin dosage” means in the muscle-growth research
Sermorelin is not growth hormone. It is a 29-amino-acid fragment of natural GHRH, and it works by prompting the pituitary gland to release the body’s own growth hormone rather than supplying GH directly [1]. That distinction changes what a “dosage” is even measuring: sermorelin trials track how much GHRH analog it takes to raise GH and IGF-1 output, not how much muscle a given milligram produces.
Four dose levels show up across the literature that touches muscle or lean mass, and they come from three very different study designs.
| Study / population | Dose studied | Duration | Reported muscle/lean-mass effect | Evidence tier |
|---|---|---|---|---|
| Pediatric GHD review [1] | 30 mcg/kg SC, nightly | Up to 12 months | Height velocity gain; not a muscle-growth endpoint | Regulatory / pediatric |
| Vittone et al., elderly men [2] | 2 mg fixed SC, nightly | 6 weeks | No change in muscle or fat on DEXA | Human pilot |
| Khorram et al., age-advanced men/women [3] | ~10 mcg/kg SC, nightly | 16 weeks (after 4-wk placebo run-in) | +1.26 kg lean mass in men only; no effect in women | Human pilot |
| Liu et al., GH meta-analysis [4] | Varied rhGH regimens (not sermorelin) | Pooled randomized trials | +2.1 kg lean mass (95% CI 1.3-2.9); no gain in strength | Human, systematic review, different drug class |
That last row matters as much as the first three. Most of the “growth hormone builds muscle” evidence base is actually drug-different: it studied recombinant human growth hormone (rhGH), not the GHRH analog sermorelin. Folding the two together is the most common error in muscle-growth marketing copy.
How sermorelin is meant to work: the GHRH-to-muscle pathway
The mechanism is straightforward even where the outcomes are not. Sermorelin binds the GHRH receptor on pituitary somatotroph cells, triggering a pulsed release of the body’s own growth hormone [1]. GH then signals the liver to raise IGF-1 output, and IGF-1 is the hormone most directly tied to skeletal-muscle protein synthesis.
Sermorelin works upstream of GH rather than replacing it, so the pituitary’s own brake, somatostatin, stays active, keeping release closer to a normal pattern than a fixed rhGH dose would. In practice, the muscle-specific human data on sermorelin itself is thin, small-sample, and decades old.
What the muscle-growth studies actually found
Higher, weight-based dosing showed a small lean-mass gain, in men only
The Khorram trial is the closest thing this compound has to a muscle-relevant human dataset. Nineteen men and women aged 55 to 71 received a nightly GHRH analog dose scaled to roughly 10 mcg/kg after a placebo run-in [3]. Men gained about 1.26 kg of lean body mass over 16 weeks; women did not. Both sexes gained skin thickness, but lean-mass benefit tracked with sex, not just dose.
Fixed, lower-intensity dosing showed no measurable muscle change
A separate trial used a flat 2 mg nightly dose, not scaled to body weight, in ambulatory men aged 64 to 76 [2]. After six weeks, DEXA scans of muscle and fat showed no change, and muscle histology was unaffected. Single nightly GHRH dosing was simply less effective than the repeated, weight-based dosing used elsewhere, a dosing-frequency finding, not a muscle-growth endorsement.
Lean mass on a scan is not the same as strength in a gym
Even in the rhGH literature, where sample sizes are far larger, the pattern holds: lean mass rises on imaging more reliably than strength rises on a dynamometer [4]. Sermorelin’s own dataset is too small to test strength separately, so reading “lean mass increase” as “stronger muscles” extrapolates past what any sermorelin trial measured.
Is sermorelin legal, and what dosage was ever FDA-approved (as of July 2026)
Sermorelin has an unusually well-documented paper trail. The FDA approved it in 1990 as a diagnostic agent (NDA 19-863) and again in 1997 as Geref (NDA 20-443) for pediatric growth hormone deficiency, at the 30 mcg/kg dose above [1]. Manufacturer EMD Serono stopped production in 2008, and the FDA withdrew both approvals effective June 18, 2009 [5].
That withdrawal was a business decision, not a safety one. A Federal Register notice published March 4, 2013 determined Geref was not withdrawn for reasons of safety or effectiveness [6]. No sermorelin product holds active FDA marketing approval today; what is sold now comes only from state-licensed compounding pharmacies under prescription.
| Aspect | Status / detail |
|---|---|
| FDA-approved indication today | None; approvals withdrawn effective June 18, 2009 [5] |
| Last FDA-approved dose | 30 mcg/kg/day SC, pediatric growth failure only [1] |
| Reason for withdrawal | Manufacturer business decision; confirmed not safety/effectiveness [6] |
| Current source | Compounding pharmacy, prescription required |
| Muscle-growth indication | Never studied at scale or FDA-evaluated for this use |
Read this before the hype: No sermorelin dosage has been FDA-approved for muscle growth in adults, and the compound is not currently sold as an approved finished drug at any dose. This page summarizes published research; it is not medical advice, a dosing guide, or an endorsement of use. Legal and compounding status can vary by state and is subject to change, so verify current status independently.
Key takeaways
- No sermorelin dosage has ever been tested specifically for muscle growth in healthy training adults; the human data comes from older-adult GH-deficiency research [2][3].
- The only dose with a measured lean-mass gain was roughly 10 mcg/kg nightly, and it worked in men only, not women, over 16 weeks [3].
- A fixed 2 mg nightly dose produced no muscle or fat change on DEXA after six weeks, suggesting dosing schedule matters as much as amount [2].
- The FDA-approved sermorelin dose, 30 mcg/kg/day, was for pediatric growth failure, a completely different goal than adult muscle building [1].
- Sermorelin carries no active FDA marketing approval today; the 2009 withdrawal was confirmed as a business decision, not a safety finding [5][6].
Frequently asked questions
What sermorelin dosage did studies use for muscle growth?
No study tested sermorelin dosage for muscle growth specifically. The closest data point is a roughly 10 mcg/kg nightly dose in a 16-week trial of older adults, where men gained about 1.26 kg of lean mass and women did not [3].
Is there an FDA-approved sermorelin dose for building muscle?
No. The only FDA-approved sermorelin dose, 30 mcg/kg/day, was for pediatric growth hormone deficiency, and that approval was withdrawn in 2009 [1][5]. No dose is approved for adult muscle growth.
Does sermorelin dosage affect men and women differently?
In the one trial that measured this, yes. A roughly 10 mcg/kg nightly dose raised lean body mass in men but not women, though skin thickness rose in both sexes [3].
How does sermorelin dosage compare to HGH dosage for muscle?
They are different drug classes. Sermorelin prompts the body to release its own GH; a pooled analysis of actual recombinant GH trials found a larger average lean-mass gain (about 2.1 kg) but no strength improvement [4].
Is sermorelin legal to use today?
Sermorelin holds no active FDA marketing approval; the last approved version was withdrawn in 2009 for business, not safety, reasons [5][6]. Where available, it comes through prescription compounding, and rules vary by state.
Does a higher sermorelin dosage mean more muscle growth?
The limited data does not support a simple dose-response line. A fixed low dose showed no effect, a weight-based higher dose showed a small effect in men only, and no trial has tested a dose range against muscle growth directly [2][3].
Sermorelin dosage research sits inside the broader growth-hormone-releasing hormone and IGF-1 literature: a GHRH analog that binds pituitary somatotroph receptors, prompts pulsatile GH release, and raises hepatic IGF-1 output, tested mainly for pediatric growth hormone deficiency and age-related GH decline rather than adult muscle building, with lean-body-mass and skin-thickness outcomes reported far more often than strength or hypertrophy; Compound Universe tracks each dosing regimen against the primary literature so the summary reflects study data rather than marketing claims.
Strip away the marketing and sermorelin dosage for muscle growth is an under-studied question, not a solved one: the doses on record come from small, decades-old trials in older adults, they produced a modest lean-mass signal in men and none in women, and no dose was tested against muscle growth as a primary goal. For a compound with no active FDA approval at any dose, that gap is the story worth remembering.
Compare next: see the full muscle-growth peptide comparison | Compound Universe’s sermorelin research summary | are peptides legal?
References
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57. PMID 18031173. DOI 10.2165/00063030-199912020-00007. (Source for mechanism and the FDA-reviewed 30 mcg/kg pediatric dose.)
- Vittone J, Blackman MR, Busby-Whitehead J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96. PMID 9005976. DOI 10.1016/S0026-0495(97)90174-8.
- Khorram O, Laughlin GA, Yen SSC. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-9. PMID 9141536. DOI 10.1210/jcem.82.5.3943.
- Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. 2007;146(2):104-115. PMID 17227934. DOI 10.7326/0003-4819-146-2-200701160-00005.
- U.S. FDA. Withdrawal of approval of NDA 19-863 and NDA 20-443 (GEREF / sermorelin acetate), effective June 18, 2009. Federal Register, 74 FR 23407 (May 19, 2009).
- U.S. FDA. Determination That GEREF (Sermorelin Acetate) Injection… Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Federal Register, 78 FR 14095, Document 2013-04827 (March 4, 2013).